Showing 1281-1290 of 5771 results for "".
- Cloudbreak Pharma Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pingueculahttps://modernod.com/news/cloudbreak-pharma-announces-positive-phase-2-results-for-cbt-004-in-patients-with-vascularized-pinguecula/2482896/Cloudbreak Pharma announced positive topline results from its phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. The multicenter, randomized, double-maske
- Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space Delivery Platformhttps://modernod.com/news/clearside-biomedical-announces-plan-to-explore-strategic-alternatives-to-advance-its-proprietary-suprachoroidal-space-delivery-platform/2482892/Clearside Biomedical announced it has initiated a formal process to explore a range of strategic alternatives aimed at maximizing shareholder value and advancing its pipeline. To support this initiative, Clearside has
- Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitishttps://modernod.com/news/krystal-biotech-announces-first-patient-dosed-in-phase-12-trial-of-kb801-for-the-treatment-of-neurotrophic-keratitis/2482883/Krystal Biotech announced that the first patient has been dosed in its phase 1/2 clinical trial (EMERALD-1), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neurotrophic keratitis (NK). KB801 is a redosable eye drop gene
- Atsena Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)https://modernod.com/news/atsena-announces-alignment-with-fda-on-regulatory-pathway-to-approval-for-atsn-201-in-x-linked-retinoschisis-xlrs/2482878/Atsena Therapeutics announced that the FDA has agreed to the expansion of the company’s ongoing phase 1/2 LIGHTHOUSE study of ATSN-201 into a continuous phase 1/2/3 trial, enabling it to serve as a pivotal trial to support a Biologics License Application (BLA) submission for the t
- BlueRock Therapeutics Announces First Patient Treated in Phase 1/2a Trial of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-announces-first-patient-treated-in-phase-12a-trial-of-opct-001-for-primary-photoreceptor-diseases/2482877/Bayer and BlueRock Therapeutics announced that the first patient received the investigational therapy in CLARICO, a phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-00
- ViaLase Announces Strategic Leadership Transitionshttps://modernod.com/news/vialase-announces-strategic-leadership-transitions/2482876/ViaLase announced changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to
- Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.https://modernod.com/news/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc/2482871/Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid block
- Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trialhttps://modernod.com/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial/2482865/Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 p
- ViGeneron Rebrands as VeonGen Therapeutics; Announces FDA Rare Pediatric Disease Designation for Lead Gene Therapyhttps://modernod.com/news/vigeneron-rebrands-as-veongen-therapeutics-announces-fda-rare-pediatric-disease-designation-for-lead-gene-therapy/2482837/VeonGen Therapeutics announced its rebranding from ViGeneron to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanc
- Atsena Therapeutics Announces Positive Clinical Data for Gene Therapy to Treat X-linked Retinoschisis (XLRS)https://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-for-gene-therapy-to-treat-x-linked-retinoschisis-xlrs/2482808/Atsena Therapeutics announced interim data from Part A of its phase 1/2 LIGHTHOUSE clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study demonstrated a favorable safety profile and compelling signs of efficacy in adul